As ICAM‐1 levels correlated with ICI therapy's positive outcomes in patients, we investigated whether ICAM‐1 affects ICI‐responsive or ‐resistant phenotypes using several syngeneic mouse tumor models. This evidence concerns the gene ICAM1 and neoplasm.